Literature DB >> 16384636

Oligodendrocyte/myelin injury and repair as a function of the central nervous system environment.

Jack Antel1.   

Abstract

Multiple sclerosis is a chronic neurologic disorder considered to result from relatively selective immune mediated injury of central nervous system (CNS) myelin and/or its cell of origin, the oligodendrocyte (OGC). Constituents of both the innate and adaptive immune systems are potential contributors to this process. Endogenous (microglia) and infiltrating (macrophages, dendritic cells) constituents of the innate immune system serve as sensors of events occurring within the CNS; their response to such events underlies the extent of their interaction (chemoattraction, antigen presentation) with the components of the adaptive immune system (alphabeta T cells, B cells) and ultimately the extent of the resultant inflammatory response. Constituents of both the innate and adaptive immune system can serve as effectors of tissue injury. The susceptibility of specific types of neural cells to injury further reflects the extent to which immune mediators modulate expression of crucial molecules (adhesion molecules, receptors) involved in effector-target interactions. Ongoing interactions between the constituents of the immune system themselves and between these constituents and neural cells are important determinants of disease recurrence and/or progression. Conversely, these interactions also impact on the mechanisms involved in target protection and repair.

Entities:  

Mesh:

Year:  2005        PMID: 16384636     DOI: 10.1016/j.clineuro.2005.11.013

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  2 in total

1.  The CNS as a therapeutic target in multiple sclerosis.

Authors:  Jack P Antel
Journal:  Curr Neurol Neurosci Rep       Date:  2008-11       Impact factor: 5.081

2.  Effects of acute and repeated exposure to lipopolysaccharide on cytokine and corticosterone production during remyelination.

Authors:  Daniella Urbach-Ross; Alexander W Kusnecov
Journal:  Brain Behav Immun       Date:  2007-05-08       Impact factor: 7.217

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.